Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 202 entries
Sorted by: Best Match Show Resources per page
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).

ACS medicinal chemistry letters

White C, McGowan MA, Zhou H, Sciammetta N, Fradera X, Lim J, Joshi EM, Andrews C, Nickbarg EB, Cowley P, Trewick S, Augustin M, von Köenig K, Lesburg CA, Otte K, Knemeyer I, Woo H, Yu W, Cheng M, Spacciapoli P, Geda P, Song X, Smotrov N, Curran P, Heo MR, Abeywickrema P, Miller JR, Bennett DJ, Han Y.
PMID: 32292563
ACS Med Chem Lett. 2020 Mar 10;11(4):550-557. doi: 10.1021/acsmedchemlett.0c00010. eCollection 2020 Apr 09.

Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients. In particular, IDO1...

Cite
White C, McGowan MA, Zhou H, et al. Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). ACS Med Chem Lett. 2020;11(4):550-557doi: 10.1021/acsmedchemlett.0c00010.
White, C., McGowan, M. A., Zhou, H., Sciammetta, N., Fradera, X., Lim, J., Joshi, E. M., Andrews, C., Nickbarg, E. B., Cowley, P., Trewick, S., Augustin, M., von Köenig, K., Lesburg, C. A., Otte, K., Knemeyer, I., Woo, H., Yu, W., Cheng, M., Spacciapoli, P., Geda, P., Song, X., Smotrov, N., Curran, P., Heo, M. R., Abeywickrema, P., Miller, J. R., Bennett, D. J., & Han, Y. (2020). Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). ACS medicinal chemistry letters, 11(4), 550-557. https://doi.org/10.1021/acsmedchemlett.0c00010
White, Catherine, et al. "Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)." ACS medicinal chemistry letters vol. 11,4 (2020): 550-557. doi: https://doi.org/10.1021/acsmedchemlett.0c00010
White C, McGowan MA, Zhou H, Sciammetta N, Fradera X, Lim J, Joshi EM, Andrews C, Nickbarg EB, Cowley P, Trewick S, Augustin M, von Köenig K, Lesburg CA, Otte K, Knemeyer I, Woo H, Yu W, Cheng M, Spacciapoli P, Geda P, Song X, Smotrov N, Curran P, Heo MR, Abeywickrema P, Miller JR, Bennett DJ, Han Y. Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). ACS Med Chem Lett. 2020 Mar 10;11(4):550-557. doi: 10.1021/acsmedchemlett.0c00010. eCollection 2020 Apr 09. PMID: 32292563; PMCID: PMC7153270.
Copy Download .nbib Format: NLM
Navigating the Next Wave of Social Media: Future Plans to Boost Dissemination of the European Association of Urology Guidelines.

European urology

Bhatt NR, Pradere B, Teoh JY, Cucchiara V, Czarniecki SW, Esperto F, Garcia Rojo E, Ribal MJ, Giannarini G.
PMID: 34740502
Eur Urol. 2022 Jan;81(1):3-4. doi: 10.1016/j.eururo.2021.10.002. Epub 2021 Nov 02.

The uptake and utilisation of social media (SoMe) in medicine are rapidly increasing, and several new platforms and media have come to the forefront in recent times. The European Association of Urology Guidelines Office Dissemination Committee is at the...

Cite
Bhatt NR, Pradere B, Teoh JY, et al. Navigating the Next Wave of Social Media: Future Plans to Boost Dissemination of the European Association of Urology Guidelines. Eur Urol. 2021;81(1):3-4doi: 10.1016/j.eururo.2021.10.002.
Bhatt, N. R., Pradere, B., Teoh, J. Y., Cucchiara, V., Czarniecki, S. W., Esperto, F., Garcia Rojo, E., Ribal, M. J., Giannarini, G. (2022). Navigating the Next Wave of Social Media: Future Plans to Boost Dissemination of the European Association of Urology Guidelines. European urology, 81(1), 3-4. https://doi.org/10.1016/j.eururo.2021.10.002
Bhatt, Nikita R, et al. "Navigating the Next Wave of Social Media: Future Plans to Boost Dissemination of the European Association of Urology Guidelines." European urology vol. 81,1 (2022): 3-4. doi: https://doi.org/10.1016/j.eururo.2021.10.002
Bhatt NR, Pradere B, Teoh JY, Cucchiara V, Czarniecki SW, Esperto F, Garcia Rojo E, Ribal MJ, Giannarini G. Navigating the Next Wave of Social Media: Future Plans to Boost Dissemination of the European Association of Urology Guidelines. Eur Urol. 2022 Jan;81(1):3-4. doi: 10.1016/j.eururo.2021.10.002. Epub 2021 Nov 02. PMID: 34740502.
Copy Download .nbib Format: NLM
Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer.

Minerva urology and nephrology

Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz PI, Chlosta P, Shariat SF.
PMID: 32993278
Minerva Urol Nephrol. 2021 Oct;73(5):610-615. doi: 10.23736/S2724-6051.20.03938-7. Epub 2020 Sep 29.

BACKGROUND: Serum albumin-to-globulin ratio (AGR) has been shown to be associated with poor prognosis in different malignancies. In this study we aimed to evaluate the predictive value of preoperative AGR for oncological outcomes in patients with radiation recurrent prostate...

Cite
Quhal F, Pradere B, Sari Motlagh R, et al. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urol Nephrol. 2020;73(5):610-615doi: 10.23736/S2724-6051.20.03938-7.
Quhal, F., Pradere, B., Sari Motlagh, R., Mori, K., Laukhtina, E., Aydh, A., Mostafaei, H., Lysenko, I., Schuettfort, V. M., Stolzenbach, F., Palumbo, C., Heidenreich, A., Briganti, A., Karakiewicz, P. I., Chlosta, P., & Shariat, S. F. (2021). Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva urology and nephrology, 73(5), 610-615. https://doi.org/10.23736/S2724-6051.20.03938-7
Quhal, Fahad, et al. "Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer." Minerva urology and nephrology vol. 73,5 (2021): 610-615. doi: https://doi.org/10.23736/S2724-6051.20.03938-7
Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz PI, Chlosta P, Shariat SF. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urol Nephrol. 2021 Oct;73(5):610-615. doi: 10.23736/S2724-6051.20.03938-7. Epub 2020 Sep 29. PMID: 32993278.
Copy Download .nbib Format: NLM
Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients.

Toxicology reports

Framery B, Gutowski M, Dumas K, Evrard A, Muller N, Dubois V, Quinonero J, Scherninski F, Pèlegrin A, Cailler F.
PMID: 31080749
Toxicol Rep. 2019 Apr 30;6:409-415. doi: 10.1016/j.toxrep.2019.04.011. eCollection 2019.

The real-time improvement of the intraoperative discrimination between different tissue types (particularly between tumor and adjacent normal tissue) using intraoperative imaging represents a considerable advance for oncology surgeons. However, the development of imaging agents is much slower than that...

Cite
Framery B, Gutowski M, Dumas K, et al. Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicol Rep. 2019;6:409-415doi: 10.1016/j.toxrep.2019.04.011.
Framery, B., Gutowski, M., Dumas, K., Evrard, A., Muller, N., Dubois, V., Quinonero, J., Scherninski, F., Pèlegrin, A., & Cailler, F. (2019). Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicology reports, 6409-415. https://doi.org/10.1016/j.toxrep.2019.04.011
Framery, Bérénice, et al. "Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients." Toxicology reports vol. 6 (2019): 409-415. doi: https://doi.org/10.1016/j.toxrep.2019.04.011
Framery B, Gutowski M, Dumas K, Evrard A, Muller N, Dubois V, Quinonero J, Scherninski F, Pèlegrin A, Cailler F. Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. Toxicol Rep. 2019 Apr 30;6:409-415. doi: 10.1016/j.toxrep.2019.04.011. eCollection 2019. PMID: 31080749; PMCID: PMC6506861.
Copy Download .nbib Format: NLM
Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy.

Journal of clinical medicine

Ploussard G, Pradere B, Beauval JB, Chevreau C, Almeras C, Suc E, Gautier JR, Laurenty AP, Roumiguié M, Loison G, Tollon C, Mourey L, Salin A, Xylinas E, Pouessel D.
PMID: 32585894
J Clin Med. 2020 Jun 23;9(6). doi: 10.3390/jcm9061962.

BACKGROUND: To compare overall survival (OS) outcomes in pN1-3 disease at the time of radical cystectomy (RC) for muscle invasive bladder according to the neoadjuvant chemotherapy (NAC) status.MATERIALS AND METHODS: This multicenter study included 450 consecutive patients undergoing RC...

Cite
Ploussard G, Pradere B, Beauval JB, et al. Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. J Clin Med. 2020;9(6)doi: 10.3390/jcm9061962.
Ploussard, G., Pradere, B., Beauval, J. B., Chevreau, C., Almeras, C., Suc, E., Gautier, J. R., Laurenty, A. P., Roumiguié, M., Loison, G., Tollon, C., Mourey, L., Salin, A., Xylinas, E., & Pouessel, D. (2020). Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9061962
Ploussard, Guillaume, et al. "Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9061962
Ploussard G, Pradere B, Beauval JB, Chevreau C, Almeras C, Suc E, Gautier JR, Laurenty AP, Roumiguié M, Loison G, Tollon C, Mourey L, Salin A, Xylinas E, Pouessel D. Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. J Clin Med. 2020 Jun 23;9(6). doi: 10.3390/jcm9061962. PMID: 32585894; PMCID: PMC7356776.
Copy Download .nbib Format: NLM
Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.

European urology

Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, Shariat SF, Ploussard G.
PMID: 34020828
Eur Urol. 2021 Nov;80(5):549-563. doi: 10.1016/j.eururo.2021.05.001. Epub 2021 May 19.

CONTEXT: Although magnetic resonance imaging (MRI) is broadly implemented into active surveillance (AS) protocols, data on the reliability of serial MRI in order to help guide follow-up biopsy are inconclusive.OBJECTIVE: To assess the diagnostic estimates of serial prostate MRI...

Cite
Rajwa P, Pradere B, Quhal F, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol. 2021;80(5):549-563doi: 10.1016/j.eururo.2021.05.001.
Rajwa, P., Pradere, B., Quhal, F., Mori, K., Laukhtina, E., Huebner, N. A., D'Andrea, D., Krzywon, A., Shim, S. R., Baltzer, P. A., Renard-Penna, R., Leapman, M. S., Shariat, S. F., & Ploussard, G. (2021). Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European urology, 80(5), 549-563. https://doi.org/10.1016/j.eururo.2021.05.001
Rajwa, Pawel, et al. "Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis." European urology vol. 80,5 (2021): 549-563. doi: https://doi.org/10.1016/j.eururo.2021.05.001
Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, Shariat SF, Ploussard G. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol. 2021 Nov;80(5):549-563. doi: 10.1016/j.eururo.2021.05.001. Epub 2021 May 19. PMID: 34020828.
Copy Download .nbib Format: NLM
Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.

Cancer immunology, immunotherapy : CII

Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, Shariat SF.
PMID: 34023914
Cancer Immunol Immunother. 2021 May 23; doi: 10.1007/s00262-021-02953-0. Epub 2021 May 23.

BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB...

Cite
Schuettfort VM, Pradere B, Trinh QD, et al. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunol Immunother. 2021;doi: 10.1007/s00262-021-02953-0.
Schuettfort, V. M., Pradere, B., Trinh, Q. D., D'Andrea, D., Quhal, F., Mostafaei, H., Laukhtina, E., Mori, K., Sari Motlagh, R., Rink, M., Karakiewicz, P. I., Chlosta, P., Yuen-Chun Teoh, J., Lotan, Y., Scherr, D., Abufaraj, M., Moschini, M., & Shariat, S. F. (2021). Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer immunology, immunotherapy : CII, . https://doi.org/10.1007/s00262-021-02953-0
Schuettfort, Victor M, et al. "Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer." Cancer immunology, immunotherapy : CII vol. (2021). doi: https://doi.org/10.1007/s00262-021-02953-0
Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, Shariat SF. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunol Immunother. 2021 May 23; doi: 10.1007/s00262-021-02953-0. Epub 2021 May 23. PMID: 34023914.
Copy Download .nbib Format: NLM
A Novel Transdermal Ketoprofen Formulation Provides Effective Analgesia to Calves Undergoing Amputation Dehorning.

Animals : an open access journal from MDPI

Mills PC, Ghodasara P, Satake N, Alawneh J, Fraser B, Kopp S, McGowan M.
PMID: 33419294
Animals (Basel). 2020 Dec 20;10(12). doi: 10.3390/ani10122442.

There is a critical need to ensure that all cattle undergoing surgical husbandry procedures are provided effective pain relief. Non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used, and typically are administered by intramuscular (IM) injection. However, administration of NSAIDs...

Cite
Mills PC, Ghodasara P, Satake N, et al. A Novel Transdermal Ketoprofen Formulation Provides Effective Analgesia to Calves Undergoing Amputation Dehorning. Animals (Basel). 2020;10(12)doi: 10.3390/ani10122442.
Mills, P. C., Ghodasara, P., Satake, N., Alawneh, J., Fraser, B., Kopp, S., & McGowan, M. (2020). A Novel Transdermal Ketoprofen Formulation Provides Effective Analgesia to Calves Undergoing Amputation Dehorning. Animals : an open access journal from MDPI, 10(12), . https://doi.org/10.3390/ani10122442
Mills, Paul C, et al. "A Novel Transdermal Ketoprofen Formulation Provides Effective Analgesia to Calves Undergoing Amputation Dehorning." Animals : an open access journal from MDPI vol. 10,12 (2020). doi: https://doi.org/10.3390/ani10122442
Mills PC, Ghodasara P, Satake N, Alawneh J, Fraser B, Kopp S, McGowan M. A Novel Transdermal Ketoprofen Formulation Provides Effective Analgesia to Calves Undergoing Amputation Dehorning. Animals (Basel). 2020 Dec 20;10(12). doi: 10.3390/ani10122442. PMID: 33419294; PMCID: PMC7766652.
Copy Download .nbib Format: NLM
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.

Critical reviews in oncology/hematology

Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF.
PMID: 34902554
Crit Rev Oncol Hematol. 2021 Dec 10;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10.

OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis...

Cite
Laukhtina E, Sari Motlagh R, Mori K, et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2021;169:103570doi: 10.1016/j.critrevonc.2021.103570.
Laukhtina, E., Sari Motlagh, R., Mori, K., Katayama, S., Rajwa, P., Yanagisawa, T., Quhal, F., Mostafaei, H., Grossmann, N. C., König, F., Aydh, A., Pradere, B., Resch, I., Merseburger, A. S., Enikeev, D., & Shariat, S. F. (2021). Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical reviews in oncology/hematology, 169103570. https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina, Ekaterina, et al. "Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes." Critical reviews in oncology/hematology vol. 169 (2021): 103570. doi: https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2021 Dec 10;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10. PMID: 34902554.
Copy Download .nbib Format: NLM
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.

OncoTargets and therapy

Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz PI, Shariat SF, D'Andrea D.
PMID: 33488094
Onco Targets Ther. 2021 Jan 13;14:315-324. doi: 10.2147/OTT.S242248. eCollection 2021.

PURPOSE: The Plasminogen Activation System (PAS) plays a role in tumor growth, invasion and metastasis and has been associated with oncological outcomes in urinary bladder carcinoma (UBC). The use of the different components of this system as molecular markers...

Cite
Grossmann NC, Schuettfort VM, Pradere B, et al. Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. Onco Targets Ther. 2021;14:315-324doi: 10.2147/OTT.S242248.
Grossmann, N. C., Schuettfort, V. M., Pradere, B., Moschini, M., Quhal, F., Mostafaei, H., Soria, F., Katayama, S., Laukhtina, E., Mori, K., Sari Motlagh, R., Poyet, C., Abufaraj, M., Karakiewicz, P. I., Shariat, S. F., & D'Andrea, D. (2021). Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and therapy, 14315-324. https://doi.org/10.2147/OTT.S242248
Grossmann, Nico C, et al. "Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets." OncoTargets and therapy vol. 14 (2021): 315-324. doi: https://doi.org/10.2147/OTT.S242248
Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz PI, Shariat SF, D'Andrea D. Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. Onco Targets Ther. 2021 Jan 13;14:315-324. doi: 10.2147/OTT.S242248. eCollection 2021. PMID: 33488094; PMCID: PMC7814246.
Copy Download .nbib Format: NLM
"You're so powerless": Takatāpui/LGBTIQ+ people's experiences before becoming homeless in Aotearoa New Zealand.

PloS one

Fraser B, Chisholm E, Pierse N.
PMID: 34928948
PLoS One. 2021 Dec 20;16(12):e0259799. doi: 10.1371/journal.pone.0259799. eCollection 2021.

Little is known in Aotearoa New Zealand about experiences of homelessness amongst Takatāpui/LGBTIQ+ identifying people, despite growing international literature regarding LGBTIQ+ homelessness. Using data from semi-structured interviews with eight people who identified as Takatāpui/LGBTIQ+ and had experienced homelessness, this...

Cite
Fraser B, Chisholm E, Pierse N. "You're so powerless": Takatāpui/LGBTIQ+ people's experiences before becoming homeless in Aotearoa New Zealand. PLoS One. 2021;16(12):e0259799doi: 10.1371/journal.pone.0259799.
Fraser, B., Chisholm, E., & Pierse, N. (2021). "You're so powerless": Takatāpui/LGBTIQ+ people's experiences before becoming homeless in Aotearoa New Zealand. PloS one, 16(12), e0259799. https://doi.org/10.1371/journal.pone.0259799
Fraser, Brodie, et al. ""You're so powerless": Takatāpui/LGBTIQ+ people's experiences before becoming homeless in Aotearoa New Zealand." PloS one vol. 16,12 (2021): e0259799. doi: https://doi.org/10.1371/journal.pone.0259799
Fraser B, Chisholm E, Pierse N. "You're so powerless": Takatāpui/LGBTIQ+ people's experiences before becoming homeless in Aotearoa New Zealand. PLoS One. 2021 Dec 20;16(12):e0259799. doi: 10.1371/journal.pone.0259799. eCollection 2021. PMID: 34928948; PMCID: PMC8687556.
Copy Download .nbib Format: NLM
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.

Critical reviews in oncology/hematology

Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF.
PMID: 34902554
Crit Rev Oncol Hematol. 2021 Dec 10;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10.

OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis...

Cite
Laukhtina E, Sari Motlagh R, Mori K, et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2021;169:103570doi: 10.1016/j.critrevonc.2021.103570.
Laukhtina, E., Sari Motlagh, R., Mori, K., Katayama, S., Rajwa, P., Yanagisawa, T., Quhal, F., Mostafaei, H., Grossmann, N. C., König, F., Aydh, A., Pradere, B., Resch, I., Merseburger, A. S., Enikeev, D., & Shariat, S. F. (2021). Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical reviews in oncology/hematology, 169103570. https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina, Ekaterina, et al. "Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes." Critical reviews in oncology/hematology vol. 169 (2021): 103570. doi: https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2021 Dec 10;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10. PMID: 34902554.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 202 entries